In a prostate cancer trial, median time without progression was 17.7 months on two drugs, 2 on one.
Kairos Pharma (KAPA) reported positive interim results from a Phase 2 trial of ENV-105 plus apalutamide in metastatic castration-resistant prostate cancer, showing a median progression-free survival of 17.7 months compared to 2 months with apalutamide alone. The trial will now focus on first-line therapy after enzalutamide. ENV-105 targets CD105, a protein linked to treatment resistance. The company is presenting these findings at the Cancer R&D 2026 conference.
How this was made
The 30-second read
Why it matters
The disclosed interim Phase 2 PFS separation is a direct efficacy signal that can shift probability-weighted expectations for continued development and future trial design, especially in the post-enzalutamide resistance setting.
Market read
Traders get a concrete interim clinical efficacy datapoint (median PFS and statistical significance) plus a stated protocol pivot to first-line therapy after enzalutamide resistance.
What to watch
Next-step design is described (first-line after enzalutamide with resistance), but the article does not provide safety/tolerability, overall survival, or details on statistical plan beyond P=0.0008, which can temper valuation.
Background
Kairos Pharma’s ENV-105 (carotuximab) targets CD105, aiming to disrupt resistance mechanisms linked to BMP-SMAD signaling under androgen receptor inhibition and radiation sensitization.
Ticker impact
Kairos Pharma reports positive interim Phase 2 results for ENV-105 plus apalutamide in mCRPC, with median PFS 17.7 months vs 2 months.
Likely upward bias as traders price improved clinical signal and potential expansion to first-line post-enzalutamide resistance cohorts.
The article discloses a statistically significant PFS separation with specific medians and a clear next-step protocol focus, which typically drives biotech sentiment and risk re-rating.
Market effects
Reinforces investor appetite for CD105/BMP-pathway targeted oncology strategies and combination approaches in mCRPC.
Primarily US small-cap biotech sentiment; limited direct cross-asset impact expected.
International conference presentation may broaden visibility among global oncology investors and collaborators.
Counterpoint
Interim analysis and conference framing may not fully de-risk endpoints, and the magnitude of control-arm PFS (2 months) could raise questions about comparability or subsequent cohort effects.
Key entities
- companyKairos Pharma Ltd.
NYSE American-listed oncology biotech developing ENV-105 (carotuximab).
- drug_candidateENV-105 (carotuximab)
CD105/BMP signaling inhibitor evaluated in Phase 2 with apalutamide for mCRPC.
- drugApalutamide
Androgen receptor inhibitor used as the comparator backbone in the Phase 2 combination study.
